Literature DB >> 11943736

Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells.

Roman Kurt Thomas1, Anne Kallenborn, Claudia Wickenhauser, Joachim Ludwig Schultze, Andreas Draube, Martina Vockerodt, Daniel Re, Volker Diehl, Jürgen Wolf.   

Abstract

Crosslinking of the transmembrane receptor CD95/Fas leads to activation of a signaling cascade resulting in apoptosis. c-FLIP is a recently described protein that potently inhibits Fas-mediated apoptosis and has been shown to be a key factor in germinal center B cell survival. Because Hodgkin and Reed-Sternberg cells in classical Hodgkin's disease (cHD) are also resistant to Fas-mediated apoptosis we studied the role of c-FLIP in classical HD. High levels of c-FLIP protein were identified in two Fas-resistant Hodgkin-derived cell lines. In contrast to other tumor cells, inhibition of protein synthesis by cycloheximide did not lead to down-regulation of c-FLIP protein in these HD cell lines. Furthermore, Fas-mediated apoptosis was only partially restored suggesting that normal regulation of c-FLIP was disrupted. The in vivo relevance of these findings was supported by demonstration of significant c-FLIP expression by immunohistochemistry in 18 of 19 evaluable cases of primary HD. Taken together, c-FLIP is constitutively expressed in HD and may therefore be a major mechanism responsible for Fas-resistance in HD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943736      PMCID: PMC1867202          DOI: 10.1016/S0002-9440(10)62578-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

1.  Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells.

Authors:  M Müschen; D Re; A Bräuninger; J Wolf; M L Hansmann; V Diehl; R Küppers; K Rajewsky
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

Review 2.  Clonal selection and learning in the antibody system.

Authors:  K Rajewsky
Journal:  Nature       Date:  1996-06-27       Impact factor: 49.962

3.  Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.

Authors:  G H Fisher; F J Rosenberg; S E Straus; J K Dale; L A Middleton; A Y Lin; W Strober; M J Lenardo; J M Puck
Journal:  Cell       Date:  1995-06-16       Impact factor: 41.582

4.  Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas.

Authors:  L Xerri; N Carbuccia; P Parc; J Hassoun; F Birg
Journal:  Histopathology       Date:  1995-09       Impact factor: 5.087

5.  FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex.

Authors:  M Muzio; A M Chinnaiyan; F C Kischkel; K O'Rourke; A Shevchenko; J Ni; C Scaffidi; J D Bretz; M Zhang; R Gentz; M Mann; P H Krammer; M E Peter; V M Dixit
Journal:  Cell       Date:  1996-06-14       Impact factor: 41.582

6.  Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells.

Authors:  J Wolf; U Kapp; H Bohlen; M Kornacker; C Schoch; B Stahl; S Mücke; C von Kalle; C Fonatsch; H E Schaefer; M L Hansmann; V Diehl
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

7.  Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient.

Authors:  H Kanzler; M L Hansmann; U Kapp; J Wolf; V Diehl; K Rajewsky; R Küppers
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

8.  Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells.

Authors:  T L Rothstein; J K Wang; D J Panka; L C Foote; Z Wang; B Stanger; H Cui; S T Ju; A Marshak-Rothstein
Journal:  Nature       Date:  1995-03-09       Impact factor: 49.962

9.  High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells.

Authors:  R C Bargou; C Leng; D Krappmann; F Emmerich; M Y Mapara; K Bommert; H D Royer; C Scheidereit; B Dörken
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

10.  Resistance to Fas-mediated apoptosis in human hepatoma cells.

Authors:  G Natoli; A Ianni; A Costanzo; G De Petrillo; I Ilari; P Chirillo; C Balsano; M Levrero
Journal:  Oncogene       Date:  1995-09-21       Impact factor: 9.867

View more
  15 in total

1.  Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma.

Authors:  Ewerton M Maggio; Anke Van Den Berg; Debora de Jong; Arjan Diepstra; Sibrand Poppema
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

2.  Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death.

Authors:  A Dutton; J D O'Neil; A E Milner; G M Reynolds; J Starczynski; J Crocker; L S Young; P G Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-19       Impact factor: 11.205

3.  cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3.

Authors:  Horst Dürkop; Burkhard Hirsch; Corinna Hahn; Harald Stein
Journal:  J Mol Med (Berl)       Date:  2005-11-25       Impact factor: 4.599

4.  Analysis of NF-κB Pathway Proteins in Pediatric Hodgkin Lymphoma: Correlations with EBV Status and Clinical Outcome-A Children's Oncology Group Study.

Authors:  Terzah M Horton; Andrea M Sheehan; Dolores López-Terrada; Robert E Hutchison; Sonia Narendra; Meng-Fen Wu; Hao Liu
Journal:  Lymphoma       Date:  2012

5.  Expression of cellular FLICE-inhibitory protein and its association with p53 mutation in colon cancer.

Authors:  Xiao-Dong Zhou; Jie-Ping Yu; Hong-Xia Chen; Hong-Gang Yu; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

Review 6.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

7.  Overexpression of cFLIP in head and neck squamous cell carcinoma and its clinicopathologic correlations.

Authors:  Xiuguo Li; Xinliang Pan; Hui Zhang; Dapeng Lei; Dayu Liu; Fenglei Xu; Xinyong Luan
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-09       Impact factor: 4.553

8.  Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model.

Authors:  Manonmani Ganapathy; Rita Ghosh; Xie Jianping; Xiaoping Zhang; Roble Bedolla; John Schoolfield; I-Tien Yeh; Dean A Troyer; Aria F Olumi; Addanki P Kumar
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

9.  Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.

Authors:  M Stacey Ricci; Zhaoyu Jin; Michael Dews; Duonan Yu; Andrei Thomas-Tikhonenko; David T Dicker; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

Review 10.  FLIP as an anti-cancer therapeutic target.

Authors:  Jin Kuk Yang
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.